Weekly Research Analysts’ Ratings Changes for Hikma Pharmaceuticals (HIK)

A number of research firms have changed their ratings and price targets for Hikma Pharmaceuticals (LON: HIK):

• 11/7/2025 – Hikma Pharmaceuticals had its “buy” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 2,170 price target on the stock.
• 11/7/2025 – Hikma Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from GBX 2,500 to GBX 2,400. They now have an “overweight” rating on the stock.
• 11/7/2025 – Hikma Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a GBX 2,360 price target on the stock.
• 11/6/2025 – Hikma Pharmaceuticals had its price target lowered by analysts at Berenberg Bank from GBX 2,510 to GBX 2,300. They now have a “buy” rating on the stock.
• 10/16/2025 – Hikma Pharmaceuticals had its price target lowered by analysts at Berenberg Bank from GBX 2,560 to GBX 2,510. They now have a “buy” rating on the stock.

Insider Transactions at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Laura Balan Balan bought 3,500 shares of Hikma Pharmaceuticals stock in a transaction dated Friday, August 22nd. The shares were purchased at an average cost of GBX 1,821 per share, with a total value of £63,735. Also, insider Victoria Hull purchased 3,214 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was acquired at an average price of GBX 1,547 per share, with a total value of £49,720.58. Insiders have acquired a total of 465,714 shares of company stock worth $741,312,558 in the last ninety days. 17.77% of the stock is owned by company insiders.

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.